Forge Therapeutics Overview
Latest Deal Amount
$11.1M
Forge Therapeutics General Information
Description
Developer of an innovative drug discovery platform designed to offer novel antibiotics to treat multi-drug resistant bacteria. The company's platform develops small molecule inhibitors targeting metalloenzymes using gram-negative bacteria, enabling healthcare professionals to access various biochemical processes and biological catalysis.to treat diseases.
Forge Therapeutics Timeline
Want to dig into this profile?
We’ll help you find what you need
Learn more
Forge Therapeutics Valuation & Funding
| Deal Type |
Date |
Amount |
Raised to Date |
Post-Val |
Status |
Stage |
| 4. Grant |
03-Jan-2019 |
$11.1M |
000.00 |
|
Completed |
Pre-Clinical Trials |
| 3. Early Stage VC (Series A) |
01-Dec-2017 |
000.00 |
000.00 |
|
Completed |
Pre-Clinical Trials |
| 2. Grant |
26-Jul-2016 |
$8.8M |
|
|
Completed |
Pre-Clinical Trials |
| 1. Accelerator/Incubator |
01-Jan-2015 |
|
|
|
Completed |
Pre-Clinical Trials |
Forge Therapeutics Competitors (9)
| Company Name |
Financing Status |
Location |
Employees |
Total Raised |
Last Financing Date/Type |
Last Financing
Amount |
| SelectX Pharmaceuticals |
Venture Capital-Backed |
Boston, MA |
00 |
000.00 |
00000000000 |
000.00 |
| 00000 000000000000 |
Formerly VC-backed |
Cambridge, MA |
00 |
00000 |
000000 - 000 |
00000 |
| 000000000 |
Venture Capital-Backed |
Basel, Switzerland |
00 |
000.00 |
0000000000 |
000.00 |
| 000000 00000000000 |
Formerly VC-backed |
San Jose, CA |
00 |
000.00 |
000000000 |
000.00 |
| 000000 00000000000 |
Corporation |
PA |
000 |
000.00 |
00000000 |
000.00 |
Forge Therapeutics Executive Team (5)
| Name |
Title |
Board Seat |
Contact Info |
| Zachary Zimmerman Ph.D |
Co-Founder, Chief Executive Officer & Board Memberg |
|
|
| Esther van den Boom |
Chief Financial Officer |
|
|
| David Puerta Ph.D |
Co-Founder, Chief Operating Officer & Vice President of Discovery |
|
|
| Seth Cohen Ph.D |
Scientific Co-Founder & Advisor |
|
|
1 Former Executive